Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Resectable Gastric/Gastroesophageal Junction Adenocarcinoma

NCT07643623 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

720

Enrollment

INDUSTRY

Sponsor class

Conditions

Resectable Gastric/Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG: tegafur, Gimeracil and Oteracil Potassium Capsules
DRUG: Sintilimab Placebo
DRUG: Sintilimab
DRUG: Ipilimumab N01
DRUG: Oxaliplatin for injection
DRUG: Ipilimumab N01 Placebo

Sponsor

Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.